It was a pleasure to speak to Christopher Cannon to discuss the much-anticipated results of the VERTIS-CV trial (ClinicalTrials.gov Identifier: NCT01986881) evaluating the efficacy and safety and cardiovascular outcomes of ertugliflozin in type 2 diabetes.
1. Could you tell us a little about the VERTIS-CV trial and its primary and secondary outcome data? (0:06)
2. What were the major safety findings, including the effects on diabetic ketoacidosis and acute kidney injury? (2:44)
3. How do these compare to data from the other SGLT2 cardiovascular outcome trials? (3:50)
4. Why do you think this study has not shown a statistically significant effect on reducing the incidence of CV disease death and heart failure hospitalisations? (4:42)
5. With an increasing number of SGLT inhibitors available, what factors should be considered in choosing between them? (6:18)
Speaker disclosure: Christopher Cannon has received research grants from Amgen, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck and Pfizer and consulting fees from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, Sanofi and Rhoshan.
Support: Interview commissioned and filming supported by Touch Medical Media.
Filmed in coverage of the ADA 2020 Virtual 80th Scientific Sessions.
Share this Video
Related Videos In Diabetes
Sanjay Kalra: Research Highlights from 2021
We were delighted to speak with our editorial board member Dr Sanjay Kalra (Bharti Hospital, Karnal, India) around last year’s research highlights in the field of diabetes and obesity. Questions In the field of diabetes and obesity, what have been the most exciting research highlights of 2021? (0:32) What is your advice for health care […]
Gian Paolo Fadini, EASD 2021: Real-world Data from the RESTORE-2 Study
touchENDOCRINOLOGY caught up with Prof Gian Paolo Fadini (University Hospital of Padova, Italy) virtually during the EASD Annual Meeting 2021 conference to discuss the real-world data from the RESTORE-2 study. Questions 1. What have randomized controlled trials taught us about the efficacy and safety of second-generation basal insulins? (00:18-01:31) 2. What were the aims, design […]
Anna-Maria Lampousi, EASD 2021: Dietary Factors and Risk of Islet Autoimmunity and Type 1 Diabetes
touchENDOCRINOLOGY caught up with Anna-Maria Lampousi (Karolinska Institutet, Stockholm, Sweden) virtually during the EASD Annual Meeting 2021 conference to discuss her systematic review and meta-analysis on dietary factors and risk of islet autoimmunity and type 1 diabetes. Questions 1. What is known about the associations between dietary components and type 1 diabetes, and what gaps […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!